Literature DB >> 1878745

Pulse exposure to protein synthesis inhibitors enhances vascular responses to des-Arg9-bradykinin: possible role of interleukin-1.

D deBlois1, J Bouthillier, F Marceau.   

Abstract

1. The modulation of the spontaneous increase in contractile responses to des-Arg9-bradykinin (des-Arg9-BK) of rabbit aortic strips incubated in vitro was studied. Rapid hypotensive responses to exogenous kinins were also measured in rabbits anaesthetized 5 h following pretreatment. 2. Continuous exposure to the protein synthesis inhibitors cycloheximide (71 microM) or anisomycin (3.8 microM) profoundly inhibited the sensitization to des-Arg9-BK in incubated aortic strips. However, temporary (3 h) inhibition of protein synthesis in vitro followed by further incubation (3 h) of tissues without inhibitor, paradoxically enhanced both the maximal contractile responses to des-Arg9-BK (1.7 microM) and the apparent affinity of the kinin without affecting contractions to noradrenaline (NA, 100 nM) at 6.5 h. 3. The stimulatory activity of the short treatment (pulse) with cycloheximide was abolished in the presence of dexamethasone sodium phosphate (100 microM throughout the incubation). The function of receptors for kinins did not appear to be altered directly by the steroid treatment. 4. Interleukin-1 beta (IL-1 beta), applied at low concentrations (100-250 pg ml-1) on aortic strips between 3 h and 6.5 h of incubation time, mimicked the selective stimulatory effect of the cycloheximide pulse on responses to des-Arg9-BK. Higher concentrations of IL-1 beta (0.5-5 ng ml-1) did not further amplify the responses to des-Arg9-BK but decreased the contractile responses to NA. 5. The modulation by IL-1 beta of vascular sensitivity to des-Arg9-BK and to NA was prevented by blockade of protein synthesis. 6. The induction in vivo by IL-1 beta (5 micrograms kg-1) or by cycloheximide (10 mg kg-1) of cardiovascular responsiveness to des-Arg9-BK was demonstrated with a blood pressure assay of exogenous kinins or with tissues isolated ex vivo 5 h after pretreatment of animals. Evidence of active disposition of cycloheximide in vivo was also obtained. 7. We propose the production of endogenous IL-1 as a possible mechanism for the enhancement of responsiveness to des-Arg9-BK observed in tissues pulsed with a protein synthesis inhibitor and for the inducing effect of cycloheximide or E. coli lipopolysaccharide in vivo. These results suggest that effects mediated by the BK1 receptor for kinins are potentially present in pathological conditions associated with IL-1 production.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1878745      PMCID: PMC1908103          DOI: 10.1111/j.1476-5381.1991.tb12300.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  Transcriptional and posttranscriptional control of c-fos gene expression in human monocytes.

Authors:  E Sariban; R Luebbers; D Kufe
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

2.  Plasma kallikrein and Hageman factor in Gram-negative bacteremia.

Authors:  J W Mason; U Kleeberg; P Dolan; R W Colman
Journal:  Ann Intern Med       Date:  1970-10       Impact factor: 25.391

3.  Further evidence for the existence of two receptor sites for bradykinin responsible for the diphasic effect in the rat isolated duodenum.

Authors:  P Boschcov; A C Paiva; T B Paiva; S I Shimuta
Journal:  Br J Pharmacol       Date:  1984-10       Impact factor: 8.739

4.  Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells.

Authors:  P Libby; J M Ordovas; K R Auger; A H Robbins; L K Birinyi; C A Dinarello
Journal:  Am J Pathol       Date:  1986-08       Impact factor: 4.307

5.  Studies on the induction of pharmacological responses to des-Arg9-bradykinin in vitro and in vivo.

Authors:  J Bouthillier; D Deblois; F Marceau
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

6.  Multiple biological activities of human recombinant interleukin 1.

Authors:  C A Dinarello; J G Cannon; J W Mier; H A Bernheim; G LoPreste; D L Lynn; R N Love; A C Webb; P E Auron; R C Reuben
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

7.  Mitogenic effect of bradykinin and of des-Arg9-bradykinin on cultured fibroblasts.

Authors:  F Marceau; B Tremblay
Journal:  Life Sci       Date:  1986-12-15       Impact factor: 5.037

8.  Inducible interleukin-1 gene expression in human vascular smooth muscle cells.

Authors:  P Libby; J M Ordovas; L K Birinyi; K R Auger; C A Dinarello
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

9.  Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro.

Authors:  C A Dinarello; T Ikejima; S J Warner; S F Orencole; G Lonnemann; J G Cannon; P Libby
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

10.  Human interleukin 1 induces interleukin 1 gene expression in human vascular smooth muscle cells.

Authors:  S J Warner; K R Auger; P Libby
Journal:  J Exp Med       Date:  1987-05-01       Impact factor: 14.307

View more
  10 in total

1.  Bradykinin stimulates NF-kappaB activation and interleukin 1beta gene expression in cultured human fibroblasts.

Authors:  Z K Pan; B L Zuraw; C C Lung; E R Prossnitz; D D Browning; R D Ye
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

2.  Vascular mode of action of kinin B1 receptors and development of a cellular model for the investigation of these receptors.

Authors:  L Levesque; G Drapeau; J H Grose; F Rioux; F Marceau
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

3.  Effects of bradykinin receptor antagonists on antigen-induced respiratory distress, airway hyperresponsiveness and eosinophilia in guinea-pigs.

Authors:  S G Farmer; D E Wilkins; S A Meeker; E A Seeds; C P Page
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

4.  B1 bradykinin receptors and sensory neurones.

Authors:  C L Davis; S Naeem; S B Phagoo; E A Campbell; L Urban; G M Burgess
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

5.  Up-regulation of [3H]-des-Arg10-kallidin binding to the bradykinin B1 receptor by interleukin-1 beta in isolated smooth muscle cells: correlation with B1 agonist-induced PGI2 production.

Authors:  J P Galizzi; M C Bodinier; B Chapelain; S M Ly; L Coussy; S Giraud; G Neliat; T Jean
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

6.  Regulation of kinin-induced contraction and DNA synthesis by inflammatory cytokines in the smooth muscle of the rabbit aorta.

Authors:  L Levesque; J F Larrivée; D R Bachvarov; F Rioux; G Drapeau; F Marceau
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

7.  Synergism between the contractile effect of epidermal growth factor and that of des-Arg9-bradykinin or of alpha-thrombin in rabbit aortic rings.

Authors:  D deBlois; G Drapeau; E Petitclerc; F Marceau
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

8.  Bradykinin receptors in mouse and rat isolated superior cervical ganglia.

Authors:  G R Seabrook; B J Bowery; R G Hill
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

9.  The longitudinal muscle of rat ileum as a sensitive monoreceptor assay for bradykinin B1 receptors.

Authors:  S Meini; A Lecci; C A Maggi
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

10.  Haemodynamic and cardiac effects of kinin B1 and B2 receptor stimulation in conscious instrumented dogs.

Authors:  P Bélichard; B Loillier; J L Paquet; J M Luccarini; D Pruneau
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.